GRI Bio, Inc.
- GRI
- NASDAQ
- Biotechnology
- Inflammation/Fibrosis Therapeutics
- Clinical-Stage Biotech
$1.45
Today +5.07%Quote Oct 19, 2026, 08:00 PM UTC
−25.00%over the last month
Max drawdown −35.8%From 1-month high −35.8%3 months −6.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
4
Founded
2009
Market value
$3.2M
Quote Oct 19
Floor
$1.36
6.2% below price
Resistance
$1.46
0.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GRIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free